Shire Human Genetic Therapies

Since its inception in 1986, the company has grown both organically and via acquisitions. Shire focuses its portfolio on providing products for specialist physicians to prescribe in markets where the company can build a significant position. This has resulted in 2009 total revenues of US $3 billion.

Shire has offices in 28 countries, and its medicines are distributed in over 50. The Company is deeply committed to its patients and their caregivers, as evidenced in its mission: to be as brave as the people we help.

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician and their patients. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), and gastrointestinal diseases (GI.)

Shire Human Genetic Therapies (HGT)

Shire HGT, a business unit within Shire, specialises in discovering and developing innovative treatments for rare genetic diseases. The Company has four marketed therapies for Hunter syndrome, Fabry disease, Gaucher disease, and Hereditary angioedima (HAE), and a robust pipeline of therapies in varying stages of development. Shire HGT employs nearly 1500 people worldwide who work across a range of research and development, production and commercial disciplines. This vastly experienced and highly dedicated business unit is driven by a common goal: to enable people with life-altering conditions to lead better lives.